Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Ligand Initiates Clinical Trial With The Selective Androgen Receptor Modulator LGD-4033, A Potential Treatment Of Muscle And Bone Disorders
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of orally administered LGD-4033.
generic viagra online
Accouncing The Leading European Congress On Cardiac Arrhythmias And Pacing: EUROPACE 2009
EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year"s event, whose main themes are atrial fibrillation and sudden cardiac death.
News of the day
Local Meeting Held In California To Discuss HIV/AIDS Spending Priorities In Face Of Proposed State Budget Cuts
The Inland Empire HIV Planning Council, an agency that makes HIV/AIDS policy in Riverside and San Bernardino counties in California, has begun a three-day summit, where they will determine how funds - primarily from HHS - will be spent, the Riverside Press-Enterprise reports. The council, which oversees spending of more than $7 million for HIV/AIDS care and treatment in the counties, said proposed cuts to HIV/AIDS programs and Medi-Cal at the state level "could affect funding and treatment priorities set by the agency," the article states. Joe Acosta, co-chair of the council said they are looking for ways to make up for the expected shortfalls. The council distributes money to about a half dozen agencies in San Bernardino and Riverside counties that provide services to more than 6,800 HIV/AIDS patients, Acosta said" (Hines, 7/18).
Mental Health

Caldera Medical Announces FDA Clearance Of Novel Treatment For Pelvic Organ Prolapse

Caldera Medical, Inc. announced that it has received FDA clearance and CE Mark certification for the Ascend Pelvic Floor Repair System with Apical Support, a novel treatment for female pelvic organ prolapse. Ascend® is the latest addition to the Caldera Medical family of products designed to treat female stress urinary incontinence (SUI) and pelvic organ prolapse (POP). Caldera"s product line includes the Desara® Sling System, a universal sling that allows surgeons their choice of multiple surgical approaches by utilizing reusable instrumentation. Caldera is the only U.S. company offering this unique solution, which benefits surgeons, hospitals, and the environment. Pelvic Organ Prolapse is one of the most common quality of life conditions facing women. In fact, nearly 50% of women who have given birth vaginally will develop this condition. Furthermore, a woman"s lifetime probability for undergoing a surgical treatment to correct POP is approximately 11%, and approximately 29% of surgically managed patients require reoperation due to reoccurrence of the condition. Patients with POP often present with a dual diagnosis of stress urinary incontinence, and Caldera"s SUI offering, Desara, can be used together in the same surgical procedure as Ascend. Ascend introduces several key differentiators to the market. Notably, Ascend provides apical support from the anterior compartment through unique implant geometry utilizing CentraSoft™ mesh technology and a patented surgical method that is designed to both reduce invasiveness and enhance patient outcomes. CentraSoft™ mesh technology provides a thin, lightweight central mesh designed to conform to the patient"s anatomy with stronger lateral arms for support. For patients with both anterior and apical defects, Ascend offers the ability to treat both defects with one surgical implant, reducing the potential for complications and the cost to the healthcare system. Bryon L. Merade, CEO, commented, "We are very excited about Ascend"s cutting edge technology and the option it provides surgeons to treat their patients with minimally invasive techniques utilizing the fewest number of implants possible. Ascend underscores our commitment to improving women"s health." Tomas Antonini, M.D. of Round Rock, TX, one of the nation"s leading urogynecologists, said, "Ascend fulfils a need surgeons have had for years for an implant that can treat both anterior compartment and apical prolapse at the same time and in the same procedure. The ability to treat these two defects with a single implant will address a common cause of failures seen in these types of repairs. Caldera has once again brought a unique technology to market in an effort to improve the treatment of pelvic organ prolapse and stress urinary incontinence." Caldera Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009